Clinical Trial Update: Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports a completed Phase 1/2 safety trial of a glycogen synthase kinase-3 (GSK3) inhibitor for Alzheimer's disease sponsored by Noscira SA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSK3 inhibitor

Snippet

Sponsor: Noscira SA | Conditions: Alzheimer´s Disease | Phase 1, Phase 2 | Status: COMPLETED